29.1.13

Role of Excisional lymph node biopsy, Core needle biopsy and FNAC in Lymphoma diagnosis


The newly developed and more sophisticated techniques for analysis of lymphoma cells have provided us with the tools necessary for precise classification of non-Hodgkin’s lymphoma. Nonetheless, routine histologic studies remain the gold standard for diagnosis. 

Excisional Biopsy
A well-processed hematoxylin and eosin (H&E) stained section of an excised lymph node is the mainstay of pathologic diagnosis. Most often, the diagnosis of difficult lesions relies heavily on a careful assessment of the underlying architecture. Lymphoma diagnoses are much less about cytologic detail and far more about altered architecture. For example, follicular small-cleaved cell lymphoma (FSC) is characterized by an abundance of neoplastic lymphoid follicles containing monomorphous small-cleaved lymphocytes. The individual cells themselves, however, are otherwise typical small cleaved lymphocytes seen in the benign follicles of reactive lymph nodes.

The loss of normal nodal architecture that accompanies an infiltrate is of paramount importance in making a diagnosis. An incisional lymph node provides only a glimpse of the architecture, making interpretation difficult. Our surgical colleagues must be instructed to biopsy the most clinically significant site, and whenever possible, to remove an intact lymph node for pathological processing. The tissue should be delivered fresh to pathology at an appropriate time of the day in order to maximize the material for lymphoma protocol studies.

Many hematopathologists prefer to triage the material using imprint preparations, whereby a fresh cut surface of the node is touched onto glass slides for Romanowsky staining. Experienced pathologists are able to make a good approximation of the disease process based on the touch prep morphology, thus resulting in the efficient ordering of additional tests.

When the size of the tissue is limiting, the first priority must be to process the material routinely for fixation and H&E sections. Properly fixed specimens can be used for regular histologic examination, paraffin(Drug information on paraffin) section immunoperoxidase staining, and depending on the fixative, for gene rearrangement studies by polymerase chain reaction (PCR). Although B5 is the optimal fixative for routine lymphoid histology and is preferred for immunoperoxidase studies, it precludes PCR studies in most laboratories. Formalin fixation is preferred when the biopsy is small because all of the above studies, including PCR, can be performed.

Diagnosing Disease at Extranodal Sites—Approximately 30% to 35% of cases of non-Hodgkin’s lymphoma in adults present primarily at extranodal sites. Much less is known about the molecular mechanisms involved in these disorders in comparison to node-based disease. Therefore, it is important to remember to process extranodal biopsy material for lymphoma protocol studies whenever there is a suspicion of a hematolymphoid neoplasm.
Molecular genetic and cytogenetic data from gastric and pulmonary resection specimens have enormous potential to provide insights into the pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphomas but, unfortunately, lymphoma protocol is frequently overlooked in this setting. Nonetheless, examination of a well-processed H&E section from an excisional biopsy by an experienced hematopathologist will be sufficient to establish a diagnosis in the majority of cases.

Needle-Core Biopsy & FNAC


Needle-core biopsies have a role in lymphoma pathology, although it remains limited.The use of 14 to 22 gauge needles under ultrasound or radiological guidance to establish a diagnosis of non-Hodgkin’s lymphoma is problematic because of technical difficulties with biopsy crush artifact, inadequate sampling, and the usual vagaries of lymphoma pathology. Although this technique has advantages over fine-needle aspiration (FNA), it should be used judiciously as a diagnostic tool for patients with suspected non-Hodgkin’s lymphoma.

Needle-core biopsies do allow a minimal assessment of architecture in addition to immunostaining procedures, but interpretation can be problematic in cases of T-cell rich B-cell lymphoma, angioimmunoblastic-type peripheral T-cell lymphoma, or MALT lymphoma where much of the lymphoid infiltrate is reactive.

A careful review of most excisional lymph node biopsies demonstrates marked cytologic and architectural variation throughout the section, underscoring the complexity of non-Hodgkin’s lymphoma diagnoses in what would otherwise be considered routine circumstances.

Needle-core biopsies are unable to detect this variability, leading to the possibility of incorrect diagnoses in many cases. Although recent studies have recommended increased use of these techniques, patient selection and failure to provide convincing evidence that the “right treatment” decision was made in the majority of cases hamper their interpretation. Also, many of these studies included patients with an established diagnosis of either non-Hodgkin’s lymphoma or Hodgkin’s disease—an approach that differs significantly from a diagnostic procedure.

In managing ill patients or those with significant comorbid disease who are unable to tolerate an invasive surgical procedure, needle-core biopsies offer a better alternative to FNA for the diagnosis of intra-abdominal or thoracic disease. Ideally, two or three cores should be obtained with one core routinely processed for histology and the remainder used for lineage and clonality studies. In this setting, cautious interpretation of the biopsy by an experienced hematopathologist and integration of the results of the ancillary studies should allow a reasonable treatment decision to be made in most cases.

24.10.12

Micropapillary Carcinoma of the Breast



-Micropapillary breast carcinoma (or invasive micropapillary carcinoma IMPC) is a type of otherwise 'typical' invasive ductal carcinoma which exhibits a unique and characteristic growth pattern.
 -Invasive micropapillary breast carcinoma is a very aggressive form of breast cancer, with a very high rate of lymph node metastasis.(The rate of lymph node involvement is estimated at between 75% and 100%).
-Skin invovlement (skin retraction) is another occassional feature of invasive micropapillary carcinoma of the breast, and is observed in about 20-23% of all cases.


Histological aspects of invasive micropapillary carcinoma of the breast

Histologically, invasive micropapillary breast carcinoma is characterized by:
-Clusters of cohesive tumor cells within quite prominent 'clear spaces', which resemble dilated angiolymphatic vessels.
-The nuclei of tumor cells around the periphery can often bulge with a kind of 'knobby' appearance.
- It is also quite common to see lymphatic involvement with invasive micropapillary breast cancers.





The aggressiveness of invasive micropapillary carcinoma may be related to the inverse polarity of the tumor cell clusters and lymphotropism

-Invasive micropapillary breast carcinoma tumors will often show lymphocytic infiltration.
-They tend to accumlate in the breast stroma, often forming a lymphoid follicle. The presence of lymphocytes within the tumor will tend to suggest a more aggressive cancer; more likely to metastize to the lymph nodes.
-Invasive micropapillary breast cancer is also characterized histologically by an 'inverse polarity' of the tumor cell clusters. To clarify, within the breast the 'functional unit' of the breast duct wall is a 'polar' double-layered tube consisting of luminal epithelial cells surrounded by myoepithelial cells and a basement membrane. In other words, there is an order; an asymmetrical organization from 'outer to inner', and without this polarity, the breast ducts would not able to properly excrete and transport breast milk. But with micropapillary breast carcinoma (and some other breast cancers) this polarity is reversed. The clusters of malignant cells which formed have the myoepithelial cells outside of the epithelial-derived cells, with the basal layer exposed.


Hormone receptor status is high for micropapillary breast cancer, somewhat against the norm
-Breast cancers which have higher positive rates for various hormone receptors are usually considered to have a more positive outlook. For one thing, they tend to be more responsive to chemotherapy.
-With invasive micropapillary breast cancers, about 70% tend to be ER positive and around 60% are positive for progesterone receptors. HER2 overexpression may be anticipated in approximately 40% of cases.
-For most breast cancers this degree of positive hormone receptivity would be a hopeful indicator.
-In invasive micropapillary breast carcinoma,however, hormone receptor status appears to have no particular significance to the outlook.

Factors most likely to affect the prognosis of invasive micropapillary breast cancer
-The mortality rate for micropapillary breast cancer is unfortunately quite high, at over 40%.
-The average interval between full presentation of the disease and death is about 3 years. -The factors which seem most likely to affect a poor prognosis are skin involvement, and nodal status.
-However, once lymph node metastasis is confirmed, the outlook for invasive micropapillary breast cancer does not differ significantly from other breast cancers which have metastized to the lymph nodes.
-Skin invasion is a signficant predictor of a poor prognosis with invasive micropapillary breast cancer, leading to mortality in about 50% of all cases in which it occurs.
-Aspects of the tumor which are most likely to influence the risk of metastasis are the histologic grade (based on the number of atypical cells and the rate of mitosis), lymphocyte infiltration, and lymphatic vessel density.

Treatment for invasive micropapillary carcinoma of the breast
-Invasive micropapillary breast carcinoma is a highly aggressive from of breast cancer which requires the earliest possible diagnosis and aggressive intervention and management.
-The high rate of local recurrence and high probability of lymph node metastasis will usually prompt the surgeon to suggest either a modified or full radical mastectomy, though breast conserving surgery is attempted in a minority of situations.
- Axillary dissection will usually accompany a modified or radical mastectomy.
-Adjuvant treatment with chemotherapy is often utilized as well, but usually only if there is evidence of axillary node metastasis, or when there is not yet lymph node metastasis but the tumor is larger than 1 cm.

2.4.12



Immunohistochemistry

Immunohistochemistry in the differential diagnosis of
clear cell carcinomas from the kidney, liver, and lung
 Clear cell carcinoma is a common specimen seen by many surgical pathologists. Given an appropriate clinical context (for example, a patient with a large kidney mass), determining the nature and origin of a clear cell carcinoma can be very easy. However, in other situations this can be a challenging task, primarily because of the tremendous degree of overlap in the morphologic appearance of clear cell carcinomas from different primary sites. This month, we discuss the utility of a number of immunostains in the differential diagnosis of the more common types of clear cell carcinoma. Clear cell carcinoma can arise as a primary site in virtually any organ in the body. It is also well known that there are many other types of clear cell neoplasms, including mesenchymal, melanocytic, neuroendocrine, and even lymphoid clear cell tumors. However, if we limit our discussion to clear cell carcinomas, in our consultation service at ONCOPATH  Diagnostics, the most common primary sites that we see are kidney, lung, and liver (clear cell hepatoma).

Low molecular weight cytokeratin should be per-formed in essentially all of these cases, primarily to document the fact that you are indeed dealing with a carcinoma, rather than another type of clear cell neo-plasm. Virtually all clear cell carcinomas of the kidney and clear cell hepatomas express low molecular weight cytokeratin, although on some occasions the expression may be focal or weak. Most clear cell carcinomas of the lung also express low molecular weight cytokeratin,although there is a subpopulation of clear cell squamous carcinomas that may lack staining with this reagent (They stain with high molecular weight cytokeratin).

High molecular weight cytokeratin (clone 34βE12) is a very useful reagent to approach thisdifferential diagnosis. In the vast majority of cases, clear cell carcinoma of the kidney and clear cell hepatoma are completely negative for reactivity with this antibody. As such, if substantial high molecular weight cytokeratin reactivity is observed, you are usually safe crossing kidney and liver off of your list of potential primary sites. Parenthetically, to my knowledge substantial expression of high molecular weight cytokeratin also renders adrenal cortical carcinoma highly unlikely.

Cytokeratin AE1/AE3 is worthwhile to employ inthis situation, primarily because most hepatomas are negative or only focally weakly reactive for this anti-body. We have seen a small number of hepatomas that express strong cytokeratin AE1/AE3, but they represent <5% of the cases of hepatoma that we see on our consultation service. As such, strong reactivity with AE1/AE3 usually allows one to place clear cell hepatoma much lower on the list of potential primary sites. The large majority of lung carcinomas express AE1/AE3, and most clear cell carcinomas of the kidney also express AE1/AE3, although it may be patchy and weak, a point to keep in mind when dealing with a small sample of tumor.



 

 

Vimentin is an important antibody for approachingthis differential diagnosis. The vast majority of hepatomas are negative for vimentin, whereas essentially all clear cell carcinomas from the kidney express vimentin. As such, substantial expression of vimentin argues against clear-cell hepatoma. Clear cell lung carcinoma expresses vimentin in a variable fashion, some cases positive, and some cases negative.
Because of its specificity for lung tumors, TTF-1 is worth adding to the antibody panel, since reactivity with TTF-1 argues in favor of pulmonary primary origin (although clear-cell squamous carcinoma of lung is TTF-1 negative). We have never seen TTF-1 reactivity in renal cell carcinoma or in hepatoma.

Monoclonal CEA can alsobe of use in this situation, since clear cell carcinoma of the kidney and clear-cell hepatoma are negative for monoclonal CEA (although we have seen a small number of hepatomas that show a focal canalicular pattern of staining with monoclonal
CEA, similar to but substantially weaker than the canalicular pattern that can be seen with polyclonal CEA). A significant proportion of pulmonary clear cell carcinomasexpress CEA, which if present argues against kidney and liver origin. By employing this relatively small panel of antibodies, one can often determine the most likely possibility for primary origin of a clear cell carcinoma. In some situations, additional immunostains may be required to firm up the diagnosis, but that discussion is beyond the scope of this newsletter.


List of all the posts

Interesting Case

Clinical History:

53 years male,History of hypertension and tachycardia,MRI abdomen:-Left adrenal mass:- size 5.8 cm Right renal mass:- size-3.0cm Microscopic examination of the renal mass showed vascular tumor with diffuse sheets of clear cells having Fuhrman grade III nuclei. There was no evidence of necrosis within the tumor. There was no evidence of extraparenchymal invasion.
Gross examination of the left adrenal gland revealed cortically centered, solid and multinodular mass measuring 6.5 x 6.0 x 5.0 cm and weighing 122 grams. The tumor was encapsulated but showed evidence of extraparenchymal penetration. The tumor had golden brown cut surface with areas of hemorrhage and necrosis. The partial nephrectomy showed 3.0cm x 3.0cm x 3.0 cm yellow solid mass which did not invade into the perinephric adipose tissue.
Microscopically, the adrenal mass had predominant diffuse sheets and focal trabecular arrangements. The former pattern was present in about third of tumor. The cells had clear cytoplasm and round to ovoid nuclei with conspicuous nucleoli. Mitotic rate was 9/50 HPF and included atypical forms. Gross necrosis and capsular invasion were documented microscopically. There was no evidence of lymphovascular invasion. Considering the above mentioned features, a Weiss histopathologic score2 of 7/9 was applied.



Discussion:

The differential diagnosis included Renal Cell Carcinoma (RCC) with contralateral adrenal metastasis, Adrenocortical carcinoma (ACC) with contralateral renal metastasis, synchronous RCC and ACC or synchronous RCC and adrenocortical adenoma. A panel of immunohistochemical stains was performed to sort out the diagnosis. Adrenal tumor demonstrated strong Vimentin positivity and is negative for CK7, CK20, E1/AE3, EMA, Synaptophysin and S100.Renal cell carcinoma was positive for CK7, AE1/AE3, EMA (weak) and Vimentin. It was negative for CK20, Synaptophysin and S100. The difference of immunoprofile between the two tumors documented that they originated from two different primaries.

Final Diagnosis:

The diagnosis of synchronous RCC and ACC rather than metastasis influences the prognosis.

Prognosis:

The longest disease free interval after removal of contralateral adrenal metastasis was 12.1 years8 and the longest crude survival was 14.3 years. In contrast non metastazing RCC has an excellent prognosis if no metastasis developed.